Figure 3.

The effect of mtDNA content on the survival of glioma patients. The median mtDNA copy number (0.86 copies) of all glioma cases was set as cutoff point. Kaplan-Meier survival analysis was performed according to variable mtDNA content in a large cohort of gliomas. The results indicated that high mtDNA content was strongly associated with good survival in glioma patients (upper panel). When the data were further stratified based on tumor grade and the presence or absence of radiotherapy, increased mtDNA content still remained associated with good survival in gliomas (middle and lower panels).